- Funding from European Community approved for collaborative research program between BIOGENERA SpA and University of Padua Posted on by adminbio in Corporate Update
- NewCap is chosen as the new investor relations firm for BIOGENERA Posted on by adminbio in Corporate Update
- BIOGENERA participated in the International Congress on Neuroblastoma ANR (Advances in Neuroblastoma Research) held in Amsterdam May 15-18, 2023 Posted on by adminbio in Event
- Thibaud Eckenschwiller has been appointed president of BIOGENERA, May 2023 Posted on by adminbio in Corporate Update
- Giacinto d’Ettorre becomes board member of BIOGENERA Posted on by adminbio in Corporate Update
- Patent Approval in Argentina Posted on by adminbio in Search
- The company ComputerShare has been chosen to manage the corporate structure of BIOGENERA. Posted on by adminbio in Corporate Update
- BIOGENERA has reached a new milestone in lung cancer treatment Posted on by adminbio in Search
- MYCN is a key target for cases of High-Risk Neuroblastoma Posted on by adminbio in Search
- Oligonucleotides represent a new frontier for expanding drug targets for targeted cancer treatment Posted on by adminbio in Search
- New drug BGA002 overcomes Neuroblastoma resistance to Retinoic Acid drug Posted on by adminbio in Search
- BIOGENERA chooses Gitti & Partners as legal advisor Posted on by adminbio in Corporate Update
